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Abstract 
Objectives: Recruiting general practitioners (GPs) and their multimorbid older patients for trials is challenging for 
multiple reasons (e.g., high workload, limited mobility). The comparability of study participants is important for inter-
preting study findings. This manuscript describes the baseline characteristics of GPs and patients participating in the 
‘Optimizing PharmacoTherapy in older multimorbid adults In primary CAre’ (OPTICA) trial, a study of optimization of 
pharmacotherapy for multimorbid older adults. The overall aim of this study was to determine if the GPs and patients 
participating in the OPTICA trial are comparable to the real-world population in Swiss primary care.
Design: Analysis of baseline data from GPs and patients in the OPTICA trial and a reference cohort from the FIRE 
(‘Family medicine ICPC Research using Electronic medical records’) project.
Setting: Primary care, Switzerland.
Participants: Three hundred twenty-three multimorbid (≥ 3 chronic conditions) patients with polypharmacy (≥ 5 
regular medications) aged ≥ 65 years and 43 GPs recruited for the OPTICA trial were compared to 22,907 older multi-
morbid patients with polypharmacy and 227 GPs from the FIRE database.
Methods: We compared the characteristics of GPs and patients participating in the OPTICA trial with other GPs and 
other older multimorbid adults with polypharmacy in the FIRE database. We described the baseline willingness to 
have medications deprescribed of the patients participating in the OPTICA trial using the revised Patients’ Attitudes 
Towards Deprescribing (rPATD) questionnaire.
Results: The GPs in the FIRE project and OPTICA were similar in terms of sociodemographic characteristics and their 
work as a GP (e.g. aged in their fifties, ≥ 10 years of experience, ≥ 60% are self-employed, ≥ 80% work in a group prac-
tice). The median age of patients in the OPTICA trial was 77 years and 45% of trial participants were women. Patients 
participating in the OPTICA trial and patients in the FIRE database were comparable in terms of age, certain clinical 
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Introduction
Globally, the population group of adults aged ≥ 65 years 
is growing faster than all other age groups combined. 
In 2019 one in every 11 persons was 65 years and over, 
this has been predicted to increase to one in six persons 
by the year 2050 [1]. With ageing societies, also come 
growing numbers of older adults with multiple chronic 
conditions. Multimorbid patients often use multiple 
medications and with polypharmacy comes a higher risk 
of using potentially inappropriate medications (PIMs). 
PIMs are medications for which the risk of potential 
adverse events outweighs the clinical benefits, such as 
when there are more effective and safer alternatives avail-
able for use in older adults [2]. The use of PIMs is associ-
ated with increased risk of adverse drug events, falls and 
cognitive impairment [3–6]. Patients with multimorbid-
ity and polypharmacy often have complex healthcare 
needs, which in turn lead to substantial health services 
use and associated costs [7]. The use of potentially inap-
propriate medications is high in this patient group [8]. In 
this context, the ‘Optimizing PharmacoTherapy in older 
multimorbid adults In primary CAre’ (OPTICA) trial was 
launched with the aim of investigating whether an elec-
tronic clinical decision support tool can help GPs to opti-
mise medication use of older multimorbid patients with 
polypharmacy.
Lack of external validity of clinical trials, the extent to 
which results can be generalised to the wider population, 
has been cited as a reason that interventions do not get 
adopted after publication of the study. One factor that 
can influence external validity is the characteristics of the 
participants recruited into the trial; that is, whether they 
are comparable (have similar characteristics) to those 
found in the real-world population [9].
Despite societal ageing and widespread multimorbid-
ity, patients with chronic conditions and older adults in 
general are often underrepresented in clinical research 
[10, 11]. Evidence from studies of younger and healthier 
participants may not be generalizable to the broader 
older multimorbid population [12]. The reasons for the 
exclusion and general underrepresentation of complex 
older adults in research are multifaceted. On the one 
hand, studies often have inclusion and exclusion criteria 
to maximise participant retention and minimise variabil-
ity among participants [13–15]. On the other hand, even 
if older multimorbid adults are not explicitly excluded, 
major barriers to recruiting this type of study partici-
pants include limited mobility (e.g. not being able to 
attend multiple appointments or complete certain tests), 
and in the case of cognitive impairment, inability to pro-
vide informed consent [14, 16, 17]. Additionally, the per-
son identifying and selecting patients for recruitment 
(e.g. member of the research team or through healthcare 
professionals with established relationships) can impact 
the external validity of participants [18]. Use of routinely 
collected patient information to identify participants for 
clinical trials is a promising method to reduce the labour 
of recruitment. However, concerns exist about the error 
rate of using electronic medical records for this [19].
Not only can the recruitment of older multimorbid 
patients be challenging, so can the recruitment of GPs 
[20]. Previous studies found that time constraints, lack of 
training, fear of loss of professional autonomy as well as 
lack of rewards and recognition are barriers to research 
participation for physicians in general [21]. Conduct-
ing clinical research in the primary care setting comes 
with additional challenges. For instance, a lack of infra-
structure, lack of financial remuneration of practice staff 
involvement, misunderstandings on how daily clinical 
work in general practice could accommodate the clini-
cal research, and seasonal changes in workload [22, 23]. 
There is the concern that GPs with specific characteris-
tics or attitudes can be motivated more easily to partici-
pate in clinical research. If true, it would mean that the 
results of an interventional study (such as our OPTICA 
trial) would not be generalizable to even the local con-
text outside of those who participated in the trial. Over-
all, little is known about whether it is possible to recruit 
characteristics (e.g. systolic blood pressure, body mass index) and health services use (e.g. selected lab and vital data 
measurements). More than 80% of older multimorbid patients reported to be willing to stop ≥ 1 of their medications 
if their doctor said that this would be possible.
Conclusion: The characteristics of patients and GPs recruited into the OPTICA trial are relatively comparable to char-
acteristics of a real-world Swiss population, which indicates that recruiting a generalizable patient sample is possible 
in the primary care setting. Multimorbid patients in the OPTICA trial reported a high willingness to have medications 
deprescribed.
Trial registration: Clinicaltrials.gov (NCT03 724539), KOFAM (Swiss national portal) (SNCTP 00000 3060), Universal Trial 
Number (U1111-1226-8013)
Keywords: Multimorbidity, Polypharmacy, Older adults, General practitioners, Clinical trial, External validity, Baseline 
characteristics
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an externally comparable sample of older multimorbid 
patients and GPs for research in primary care.
Further, past medication optimization interventions in 
patients with polypharmacy have shown limited effect 
in changing medication use [24, 25] and/or clinical out-
comes (e.g. mortality, cognitive decline) [26]. This may be 
due to patient resistance to medication changes and their 
unawareness of potentially inappropriate medication use 
[27]. It is therefore important to consider not only the 
characteristics of participants, but their attitudes as well.
The ‘Family medicine ICPC Research using Electronic 
medical records’ (FIRE) database is the largest Swiss elec-
tronic database containing anonymized routine patient 
data from the electronic medical records in > 10% of 
Swiss primary care practices. It also contains information 
about the GPs who regularly export data from their elec-
tronic medical records. The FIRE database therefore pro-
vides a unique opportunity to examine the likely external 
validity of the OPTICA study results to the wider Swiss 
general population in primary care.
The overall aim of this study was to determine if the 
GPs and patients participating in the OPTICA trial 
are comparable to the real-world population in Swiss 
primary care. We hypothesised that our broad inclu-
sion criteria and support provided to participating GPs 
would result in recruitment of comparable participants. 
This information is not only important for interpret-
ing the forthcoming results of the OPTICA trial (i.e. the 
likely external validity of the study findings), but can also 
inform the ability to recruit complex older adults for clin-
ical trials in primary care.
Specifically, the aims of this manuscript were to:
1. Describe the baseline characteristics of participants 
(GPs and older patients with multimorbidity and 
polypharmacy) recruited to the OPTICA trial.
2. Compare the characteristics of GPs and patients par-
ticipating in the OPTICA trial with those in the FIRE 
database.
3. Compare the characteristics of the patients recruited 
for OPTICA from random screening lists gener-
ated from electronic medical records with patients 
recruited through GP identification of eligible 
patients.




For this analysis we used baseline data from the ongoing 
cluster-randomized controlled trial (cRCT) ‘Optimiz-
ing PharmacoTherapy in older multimorbid patients In 
primary CAre’ (OPTICA). We were able to compate the 
OPTICA study participants to reference cohorts from 
the ‘Family medicine ICPC Research using Electronic 
medical records’ (FIRE) project database, as all GPs who 
participated in the OPTICA trial regularly export data to 
the FIRE project. Details about these two research pro-
jects have been reported elsewhere [28, 29].
The FIRE project is the largest Swiss database collect-
ing anonymized routine patient data from the electronic 
medical records in primary care practices since 2009 
[28]. The following information is available in the FIRE 
database: administrative information (patient, age, and 
sex), diagnosis codes, laboratory and vital signs meas-
urements, and prescribing information. As of October 
2020, the database of the FIRE project contains data from 
the electronic medical records of more than 680 GPs 
(about 11% of all GPs in Switzerland [30]) and more than 
830,000 patients (about 10% of the Swiss population) 
[31]. All GPs in Switzerland are invited to join the FIRE 
project if they use an electronic health record (EHR) pro-
gram that is compatible with exporting anonymized data 
to the FIRE project.
The OPTICA trial is a cluster-randomized controlled 
trial, being conducted in primary care in the German speak-
ing part of Switzerland. The aim of the OPTICA trial is to 
investigate whether the use of an electronic clinical deci-
sion support system, namely the ‘Systematic Tool to Reduce 
Inappropriate Prescribing’ (STRIP) Assistant [32], improves 
medication appropriateness compared to a standard care 
sham intervention in older multimorbid patients with poly-
pharmacy. The STRIP Assistant (STRIPA) is based on the 
algorithms of the ‘Screening Tool to Alert doctors to Right 
Treatment’ (START) and ‘Screening Tool of Older Person’s 
Prescriptions’ (STOPP) version 2 [33], which are lists of 
medications generally considered to be inappropriate and 
appropriate in older adults, respectively [34]. The standard 
care sham intervention in the control group consists of a 
medication discussion between GPs and patients in accord-
ance with usual care. The co-primary outcomes of the 
OPTICA trial are the ‘Medication Appropriateness Index’ 
(MAI) and the ‘Assessment of underutilization’ (AOU) 
[35–37]. More detailed background information about the 
OPTICA trial, the study intervention, and the FIRE project 
is reported in eAppendix 1 in the supplement.
Participants
OPTICA trial
We present the inclusion and exclusion criteria for GPs 
and patients in the OPTICA trial in Table 1. To maximise 
the generalizability of the study population, we kept the 
exclusion criteria to a minimum. Patients were recruited 
through their GPs. GPs were instructed to use a random 
screening list generated from the data they exported to 
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the FIRE project, but also had the flexibility to recruit 
other eligible patients after exhausting the screening lists. 
The calculated sample size of the OPTICA trial was 320 
patients (details reported in the OPTICA protocol paper 
[29]).
FIRE project reference cohort
As of May 2019, around 520 GPs participated in the FIRE 
project. To define the target population of patients, we 
identified patients in the FIRE database who were at least 
65 years and were prescribed at least 5 different medica-
tions at the time point of May  1st, 2019. The selection of 
reference GPs for the analyses took place as follows: GPs 
participating in the FIRE project, who were the GP of one 
of the patients included in the patient reference popula-
tion (as described above) were included in the GP refer-
ence cohort (n = 227). GPs who participated in FIRE, but 
did not have any older multimorbid patients with polyp-
harmacy (e.g. because they had only recently joined the 
project and did not yet export data) and those who took 
place in the OPTICA trial (n = 43) were excluded from 
the GP reference cohort. eFigure 1 in the supplement vis-
ualizes the creation of the reference cohorts.
Data query and variables
From the FIRE database we extracted patients and GP 
characteristics. For GPs we extracted sociodemographic 
information and variables describing their work as GP 
(as shown in Table 2). For patients we extracted sociode-
mographic information, clinical parameters and variables 
describing their health services use (Table  3). All varia-
bles measuring health services use or reporting vital data 
and lab values were reported for the period of the last 
12 months before May 2019.
The information on patients’ willingness to have medi-
cations deprescribed was collected in the baseline phone 
call conducted with participants in the OPTICA trial 
using the German translation of the revised Patients’ 
Attitudes Towards Deprescribing (rPATD) question-
naire. The original questionnaire was developed by Reeve 
et al. [38, 40]. The German translation was validated and 
used in a Swiss study on patients’ attitudes towards hav-
ing medication deprescribed [39]. The rPATD question-
naire for both caregivers and patients contains two global 
questions as well as questions grouped into four factors: 
medication burden, mediation appropriateness, concerns 
about stopping, and involvement. There are four to five 
questions per factor, which can be used to calculate a fac-
tor score. Each factor score ranges from 1 to 5 [40].
Statistical analysis
First, we compared the characteristics of GPs participat-
ing in the OPTICA trial with those of the reference GPs 
in the FIRE database. Second, we compared the charac-
teristics of the OPTICA study participants with those of 
other older, multimorbid patients in the FIRE database. 
Third, we compared the characteristics of the patients 
recruited for OPTICA from the random screening lists 
with the OPTICA patients recruited directly by GP iden-
tification of eligible participants (i.e. not from the screen-
ing lists). Finally, we described patients’ willingness to 
have medications deprescribed. We also performed a 
sensitivity analysis, by comparing the characteristics 
of the OPTICA study participants with all other older 
patients of the same GP only.
Categorical data are presented as frequencies and 
percentages, and continuous variables as median and 
interquartile range (IQR), as the variables were non-
normally distributed. For categorical variables we per-
formed a Fisher’s exact text and for continuous variables 
a Kruskal–Wallis test was performed, as defined in the 
R package “tableone” [41]. For this study, if the p-value 
was < 0.05 we concluded that there was sufficient evi-
dence to say that the groups were statistically different. 
We also calculated standardized differences, which can 
be used to compare balances in measured variables [42]. 
While p-values were used for the statistical hypothesis 
testing, absolute standardized difference (ASD) values 
helped quantify the differences between groups. An ASD 
value > 0.2 has previously been defined as representing an 
imbalance between two groups [43]. Hence for the pur-
pose of this study we considered a maximum threshold of 
0.2 for ASD value as being acceptable in terms of compa-
rability of the two groups. The group comparisons were 
performed using the statistical software package R (Ver-
sion 3.6.3) [44].
The analyses on patients’ willingness to deprescribe 
were performed using the statistical software Stata 15.1 
(StataCorp, College Station, TX, USA). We calculated the 
four factor scores (involvement, burden, appropriateness, 
and concerns about stopping) as described previously 
[40]. Each score is calculated based on responses to the 5 
items within each factor of the rPATD questionnaire and 
ranges from 1–5. In addition, we present the responses to 
the two stand-alone statements from the rPATD (“Over-
all, I am satisfied with my current medicines” and “If my 
doctor said it was possible I would be willing to stop one 
or more of my regular medicines”).
Patient and public involvement
As described in the OPTICA protocol paper [29], GPs 
and older patients with multimorbidity and polyphar-
macy are represented in the independent Safety and 
Data Monitoring Board of the OPTICA trial. GPs partic-
ipating in the OPTICA trial receive regular newsletters. 
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At the end of the study, study participants are informed 
about their study allocation and the results of the study.
Results
The process of the recruitment of GPs and patients in the 
OPTICA trial is shown in the trial flow chart (Fig. 1). Out 
of 121 GPs showing interest in the OPTICA trial, 94 were 
contacted for a recruitment visit in their GP office (expla-
nation of study design, tasks for participating GPs, and if 
needed, installation of FIRE data export tools), and 43 were 
recruited. Out of 934 patients on the screening lists, 224 
were recruited. Additionally, 99 patients (30.6% of the total 
patients recruited) were recruited through GP identification 
of eligible patients (outside of the screening list).
What types of GPs participated in the OPTICA trial, 
and how did they compare to the non‑participating GPs 
from FIRE?
As shown in Table  2, GPs who participated in OPTICA 
and those from the FIRE reference cohort were in their fif-
ties on average (OPTICA median = 54, FIRE median = 51), 
had several years of experience working as a GPs (OPTICA 
median = 15, FIRE median = 10), and the majority were 
self-employed (OPTICA self-employed = 70%, FIRE self-
employed = 63%). The GPs in the FIRE reference cohort 
and OPTICA were similar in terms of age, median years 
since starting to work as a GP, employment status, GP 
practice type, and participation in integrated care mod-
els (p-values > 0.05 and absolute standardized differences 
(ASD) < 0.2). We found differences between OPTICA and 
Table 2 Baseline characteristics of general practitioners in the OPTICA trial compared to the general practitioners in the FIRE database
Abbreviations: GP General practitioner, IQR Interquartile range, OPTICA Optimizing PharmacoTherapy in older multimorbid adults In primary CAre, FIRE Family 
medicine ICPC Research using Electronic medical records
1 As of spring May 2019, excludes GPs who were part of the OPTICA trial and who did not have any eligible patients for the OPTICA trial
2 Depending on the area/region they work in, GPs in Switzerland may be able to sell and dispense medications to their patients
3 Only for selected medications
4  ≥ 5 medications from different ATC groups and age ≥ 65 years. The other inclusion and exclusion criteria were not implemented, as they had to be double checked 
by the GPs
5 For categorical variables we performed a Fisher’s exact text and for continuous variables a Kruskal–Wallis test was performed; P-values of < 0.05 represent that there 
is evidence for a statistically significant difference between the two groups
6 An imbalance between the two groups was previously defined as an absolute standardize difference value > 0.2
Characteristics OPTICA GPs (N = 43) FIRE GPs (N = 227)1 P‑value5 Absolute 
standardized 
difference6
Median age (IQR) 54 (45–60) 51 (44–58) 0.572 0.073
Median years since starting to work as GP (IQR) 15 (6–23) 10 (5–21) 0.302 0.159
Sex
 Women (%) 8 (19) 80 (35) 0.034 0.385
 Men (%) 35 (81) 146 (65)
Employment status
 Self-employed (%) 28 (70) 131 (63) 0.474 0.143
 Employed (%) 12 (30) 76 (37)
GP practice type
 Group practice (%) 36 (84) 200 (88) 0.452 0.126
 Single practice (%) 7 (16) 27 (12)
Location
 Non-urban (%) 17 (40) 51 (23) 0.022 0.375
 Urban (%) 26 (60) 176 (78)
Self-dispensation of medications in GP  office2
 Yes (%) 25 (60) 175 (77) 0.046 0.386
 No (%) 13 (31) 41 (18)
  Limited3 (%) 4 (10) 11 (5)
Median work percentage (IQR) 80 (80–100) 80 (60–100) 0.020 0.401
Participation in integrated care model
 Yes 39 (93) 202 (95) 0.456 0.103
 No 3 (7) 10 (5)
Median percentage of eligible patients based on 
OPTICA inclusion criteria (IQR)4
6 (3–14) 7 (4–11) 0.614 0.287
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GPs from the FIRE reference cohort with regards to sex 
(lower proportion of female GPs in the OPTICA trial), 
location (greater proportion of OPTICA GPs in non-
urban areas), and self-dispensing of medications in GP 
office (lower proportion of OPTICA GPs than FIRE GPs). 
The median work percentage was 80% in both groups 
(4-day week), but p-value and ASD showed that the dis-
tribution of the work percentages was different between 
groups.
What types of patients consented to participate 
in the OPTICA trial, and how did they compare 
to non‑participants?
As shown in Table 3, patients participating in the OPTICA 
trial were relatively comparable to other older patients 
with multimorbidity in the FIRE reference cohort with 
regards to their clinical characteristics and health services 
use. On average, patients were in their late seventies 
(OPTICA median = 77, FIRE median = 78), and regu-
larly saw their GP (OPTICA median consultation counts 
in the last 6 months = 16, FIRE median = 13). We did not 
find evidence for a difference between the groups with 
regards to age, the median number of Body Mass Index 
(BMI) measurements, the median number of lipid profile 
measurements, median systolic blood pressure, median 
BMI and median number of glomerular filtration rate 
(GFR) measurements (p-values > 0.05 and ASD < 0.1 for 
all these variables). Median diastolic blood pressure and 
median HbA1c values were found to be statistically signifi-
cant between groups, but the ASD was close or equal to 
0.1. For most of the remaining variables, we found statis-
tically significant differences and standardized differences 
of around 20% (e.g. sex, median number of consulta-
tions, median number of medications, etc.). On average, 
Table 3 Baseline characteristics of patients in the OPTICA trial compared to other multimorbid patients with polypharmacy in the FIRE 
database
Abbreviations: BMI Body Mass Index, IQR Interquartile range, GFR Glomerular filtration rate, HbA1c Hemoglobin A1C, OPTICA Optimizing PharmacoTherapy in older 
multimorbid adults In primary CAre, FIRE Family medicine ICPC Research using Electronic medical records
1 Patients who participated in the OPTICA trial
2 Patients eligible to participate in the OPTICA trial based on the inclusion and exclusion criteria, excludes patients who participated in the OPTICA trial
3 For categorical variables we performed a Fisher’s exact text and for continuous variables a Kruskal–Wallis test was performed. P-values of < 0.05 represent that there 
is evidence for a statistically significant difference between the two groups
4 An imbalance between the two groups was previously defined as an absolute standardize difference value > 0.2
5 Chronic conditions were defined according to Lamers et al. and O’Halloran et al. [38, 39]
6 Number of medications belonging to different groups defined by the Anatomical Therapeutic Chemical (ATC) classification system
Characteristics OPTICA study 
participants1 
(N = 323)
Patients in the FIRE 




Median age (IQR) 77 (73–83) 78 (72–84) 0.630 0.053
Sex
 Women (%) 146 (45) 12′699 (55) 0.001 0.206
 Men (%) 177 (55) 10′207 (45)
Median number of chronic conditions (IQR)5 4 (3–6) 3 (3–5)  < 0.001 0.422
Median number of medications in the last 12 months (IQR)6 6 (5–9) 7 (5–8)  < 0.001 0.23
Health services use (in the last 12 months)
 Median number of consultations (IQR) 16 (10–25) 13 (7–22)  < 0.001 0.216
 Median number of blood pressure measurements (IQR) 3 (2–5) 2 (1–4)  < 0.001 0.276
 Median number of Body Mass Index measurements (IQR) 2 (1–3) 1 (1–3) 0.501 0.03
 Median number of HbA1c measurements (IQR) 2 (1–4) 2 (1–3) 0.001 0.24
 Median number of glomerular filtration rate (GFR) measure-
ments (IQR)
2 (1–3) 1 (1–3)  < 0.001 0.208
 Median number of lipid profile measurements (IQR) 1 (1–2) 1 (1–1) 0.166 0.093
Lab values & vital signs (in the last 12 months)
 Median systolic blood pressure (IQR) 138 (126–148) 138 (127–149) 0.541 0.023
 Median diastolic blood pressure (IQR) 76 (70–83) 79 (72–85) 0.005 0.154
 Median Body Mass Index (IQR) 29 (25–32) 28 (24–31) 0.235 0.101
 Median HbA1c (IQR) 6.3 (5.7–7) 6.1 (5.6–6.9) 0.023 0.1
 Median GFR (IQR) 66.2 (51.4–79.7) 68.3 (52.3–82.5) 0.314 0.041
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patients in the OPTICA trial had more chronic conditions 
(OPTICA median = 4, FIRE median = 3, ASD = 0.422), but 
less medications (OPTICA median = 6, FIRE median = 7, 
ASD = 0.23). Within patients of the same GP, patients par-
ticipating in OPTICA were comparable to patients not 
participating in OPTICA (eTable 1 in the supplement).
How did patients recruited from random screening lists 
and other patients compare?
Two hundred and twenty-four patients were recruited 
from the random screening lists and 99 patients were 
recruited outside of these lists. The comparison of 
these two group (Table 4) found that they were compa-
rable. We only found a statistically significant difference 
concerning median number of consultations (p = 0.031) 
and number of BMI measurements (p = 0.022).
What was study participants’ willingness to have 
medications deprescribed?
As shown in Table 5, at baseline of the OPTICA trial, the 
majority of patients in the OPTICA trial (> 90%) reported 
to be satisfied with their current medications. Further-
more, most of the study participants (> 80%) reported 
to be willing to stop one or more of their medications if 
their doctor said that it was possible. The OPTICA study 
participants reported to be involved in their medication 
use (median involvement score = 4.8 (IQR = 4.2–5.0); 
score can range from 1 to 5, with 5 representing a high 
reported involvement). The median medication burden 
score was 2.2 (IQR = 1.6–2.8) and the concerns about 
stopping score was 1.6 (IQR = 1.0–2.4). Results of car-
egivers who completed the caregiver rPATD (where the 
patient was unable to complete the questionnaire due to 
cognitive impairment, n = 16) are shown in Table 5.
Fig. 1 Flow chart of recruitment of general practitioners and patients in the OPTICA  trial1. 1cluster-randomized controlled trial in Swiss primary care. 
Abbreviations: OPTICA = Optimizing PharmacoTherapy in older multimorbid adults In primary CAre
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Discussion
To inform the likely external validity of the results of the 
OPTICA trial, we compared the characteristics of our 
participating GPs and patients to a Swiss real-world ref-
erence cohort. We also examined the characteristics of 
patients recruited based on random screening lists (cre-
ated from electronic medical records) and those recruited 
outside of these lists by their GP to see whether a bias in 
the selection may exist.  Finally we explored the willing-
ness of patients in OPTICA to have medications depre-
scribed which allows us to reflect on the possible impact 
that this may have on the outcomes of the trial and com-
pare them to previously studied populations. From our 
analyses we have some confidence that the findings of the 
OPTICA study will be generalizable to the broad Swiss 
population of GPs and patients. We found that the GPs 
in the FIRE project and OPTICA were similar in terms of 
sociodemographic characteristics and their work as a GP 
(e.g. age, experience as GP, employment status, and GP 
practice type). We also found that patients participating in 
the OPTICA trial and patients in the FIRE database were 
comparable in terms of age, median number of certain lab 
and vital data measurements (e.g. BMI, lipid profile, GFR 
measurements) and certain clinical characteristics (e.g. 
systolic blood pressure, BMI). For the variables that dif-
fered between the two groups according to the statistical 
tests, the absolute standardized differences were generally 
around 0.2 (or 20%), with an imbalance of the two groups 
having previously been defined as > 0.2. Patients who par-
ticipated in the OPTICA trial reported a high level of will-
ingness to stop one or more of their medications.
Overall, our study results showed that GPs who partici-
pated in the OPTICA trial and those who participated in 
the FIRE project were comparable in most of the variables 
examined. Previous research showed that high perform-
ing physicians are more likely to participate in research 
[45]. When looking at the patient data, we observed that 
OPTICA patients had more chronic conditions, but less 
medications. The absolute standardized differences indicate 
some imbalances between the groups on these variables. 
Table 4 Baseline characteristics of patients in the OPTICA trial who were recruited from the screening list and those who were 
recruited outside of the screening list
Abbreviations: BMI Body Mass Index, IQR Interquartile range, GFR Glomerular filtration rate, HbA1c Hemoglobin A1C, OPTICA Optimizing PharmacoTherapy in older 
multimorbid adults In primary CAre
1 For categorical variables we performed a Fisher’s exact text and for continuous variables a Kruskal–Wallis test was performed. P-values of < 0.05 represent that there 
is evidence for a statistically significant difference between the two groups
2 An imbalance between the two groups was previously defined as an absolute standardize difference value > 0.2
Characteristics OPTICA study participants 
from screening list (N = 224)
OPTICA study participants 





Median age (IQR) 77 (72–82) 79 (74–84) 0.088 0.183
Sex
 Women (%) 106 (47) 40 (40) 0.276 0.14
 Men (%) 118 (53) 59 (60)
Median number of chronic conditions (IQR) 4 (3–6) 4 (3–6) 0.774 0.086
Median number of medications in the last 12 months 
(IQR)
6 (5–9) 7 (3–9) 0.464 0.16
Health services use (in the last 12 months)
 Median number of consultations (IQR) 17 (10–26) 14 (9–21) 0.031 0.303
 Median number of blood pressure measurements 
(IQR)
3 (2–6) 3 (1–5) 0.197 0.034
 Median number of Body Mass Index measurements 
(IQR)
1 (1–2) 2 (1–3) 0.255 0.329
 Median number of HbA1c measurements (IQR) 2 (1–3) 2 (1–4) 0.332 0.147
 Median number of glomerular filtration rate (GFR) 
measurements (IQR)
2 (1–3) 2 (1–3) 0.901 0.045
 Median number of lipid profile measurements (IQR) 1 (1–2) 1 (1–2) 0.667 0.101
Lab values & vital signs (in the last 12 months)
 Median systolic blood pressure (IQR) 137 (125–147) 139 (130–150) 0.397 0.102
 Median diastolic blood pressure (IQR) 76 (70–83) 76 (71–83) 0.801 0.078
 Median Body Mass Index (IQR) 29 (25–32) 29 (25–33) 0.902 0.015
 Median HbA1c (IQR) 6.3 (5.8–7.0) 6.4 (5.6–7.0) 0.991 0.02
 Median GFR (IQR) 66.5 (53.4–80.1) 62.7 (48–6-78.9) 0.264 0.167
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While one can argue about whether the differences are 
clinically relevant, this observation could indicate that 
GPs in the OPTICA trial may have been more proactive in 
reviewing the medications of their patients than other GPs. 
If the latter was the case, this would mean that the inter-
vention of the OPTICA trial may be limited in its effect 
(i.e. if the patients had little room for further optimisation 
of their medications). We also found differences in sex, 
location and self-dispensing between GPs in both groups. 
These differences may have stemmed from the recruitment 
strategy used in the OPTICA trial, which in the context of 
difficulties of recruiting GPs for clinical research focused 
(and therefore needing to optimise GP recruitment) did not 
specifically recruit based on their baseline characteristics. 
The sex composition of the OPTICA GPs could affect the 
final results, since female physicians have been found to be 
less likely to make deprescribing decisions [46].
We found that the multimorbid older patients who par-
ticipated in the OPTICA trial were comparable to those in 
the FIRE database in terms of sociodemographic variables, 
health services use and clinical characteristics. For the 
variables were there was a statistically significant difference 
between the groups, most had standardized differences 
close but not passing the ASD threshold of 0.2 for meaning-
ful differences between the groups (e.g. number of medica-
tions: OPTICA median = 6, FIRE median = 7, ASD = 0.23, 
number of consultations OPTICA median = 16, FIRE 
median = 13, ASD = 0.216). There is a lower proportion of 
female participants in the OPTICA trial than in the refer-
ence FIRE cohort. However, since no difference in willing-
ness to deprescribe according to sex has been identified 
[39, 47], we do not anticipate that this sex imbalance will 
affect the results of the OPTICA trial.
We found that the trial participants recruited from the 
random screening lists (around two thirds of patients) and 
those who were recruited outside of these lists (around 
one third of patients) were comparable. While system-
atic differences in recruitment behaviour (i.e. differential 
recruitment [48]) has been reported previously in the con-
text of a cluster-randomized controlled trial in primary 
care (UK BEAM trial) [49], we did not find evidence for 
a bias in the selection of participants in the OPTICA trial. 
Table 5 Patients’ and caregivers’ willingness to have medications deprescribed assessed with ‘revised Patients’ Attitudes Towards 
Deprescribing’ (rPATD)  questionnairea
Abbreviations: OPTICA Optimizing PharmacoTherapy in older multimorbid adults In primary CAre, rPATD Revised Patients’ Attitudes Towards Deprescribing
a Reeve, E., Low, L. F., Shakib, S., & Hilmer, S. N. (2016). Development and Validation of the Revised Patients’ Attitudes Towards Deprescribing (rPATD) Questionnaire: 




Caregivers of OPTICA participants 
with cognitive impairment (n = 16)
“Overall, I am satisfied with my current medicines” (%) and respectively “Overall, I am satisfied with my care recipient’s current medicines”
 Strongly agree 215 (72.2) 11 (68.7)
 Agree 64 (21.5) 5 (31.3)
 Unsure 4 (1.3) -
 Disagree 11 (3.7) -
 Strongly disagree 4 (1.3) -
“If my doctor said it was possible I would be willing to stop one or more of my regular medicines” (%) and respectively “If their doctor said it was pos-
sible I would be willing to stop one or more of my care recipient’s medicines”
 Strongly agree 224 (75.2) 10 (62.5)
 Agree 38 (12.8) 3 (18.8)
 Unsure 9 (3.0) 1 (6.3)
 Disagree 14 (4.7) 1 (6.3)
 Strongly disagree 13 (4.4) 1 (6.3)
Factor scores
 Involvement: Median involvement in medication management score (IQR) 4.8 (4.2–5.0) 4 (3.4–5.0)
[range: 1–5, the higher the score the more ‘involved’ patients are with their medications and caregivers with the medications of the person they care 
for]
 Burden: Median perceived burden of medications score (IQR) 2.2 (1.6–2.8) 2.3 (1.3–3.8)
[range: 1–5, the higher the score the more burdensome patients and caregivers perceive/view/experience the medications to be]
 Appropriateness: Median belief in appropriateness of medications score (IQR) 3.8 (3.4–4.2) 3.8 (3.4–4.2)
[range: 1–5, the higher the score the more appropriate patients respectively caregivers perceive/view/experience the medications]
 Concerns about stopping: Median concerns about stopping medications score (IQR) 1.6 (1.0–2.4) 1.2 (0.8–1.6)
[range: 1–5, the higher the score the potential concerns patients respective caregivers have about stopping one or more of the medications]
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The UK BEAM trial reported, for example, that patients in 
participating practices were experiencing milder back pain 
(which the intervention targeted) than those in the control 
group and thus highlighted the potential for the recruit-
ment process to bias study results [49]. The use of random 
screening lists helped to standardize patient recruitment 
but, in light of the imperfect nature of the screening lists, 
we also allowed GPs to recruit patients who were not on 
these lists. We assumed that giving participating GPs some 
flexibility in the recruitment process would allow them to 
better integrate recruitment into their regular practice and 
would therefore optimise recruitment.
Concerning patients’ willingness to deprescribe, we 
found that the OPTICA study participants had a high 
involvement in their medication use and > 80% were will-
ing to stop one or more of their regular medications if their 
doctor told them this was possible. These findings are in 
line with previous research. Another study conducted in 
Switzerland found that 77% of older adults would be will-
ing to stop one or more of their medications [39] and simi-
lar proportions were found in studies in other countries 
(88% in Australia [47], 92% in the United States [50], 83% 
in Singapore [51]). While these numbers have to be inter-
preted with caution (e.g. social desirability bias, not medi-
cation specific, hypothetical nature of the question), it 
shows that older patients may be open to optimizing their 
medication use through deprescribing. We also found the 
factor scores to be comparable to the results from a study 
in Australian older adults [47]. This information is cru-
cial for implementing medication optimization interven-
tions, and in the context of the OPTICA trial, it shows that 
patients’ attitudes towards deprescribing may not be a bar-
rier to implementation of deprescribing.
While the results presented in this manuscript are pri-
marily Swiss-specific, we can draw a more broadly appli-
cable conclusion; it appears to be possible to recruit a 
sample of study participants in primary care trials that is 
comparable to real life cohorts.
Strengths & limitations
The OPTICA trial had a low number of exclusion criteria, 
which facilitated broad recruitment of study participants. 
However, the analyses in this manuscript have several limi-
tations. First, in Switzerland there are no complete GP or 
patient registries. The FIRE project maintains the only pri-
mary care database in Switzerland of this size, but it does 
not include all GPs in Switzerland, and in turn, does not 
include all patients in Switzerland. In Switzerland, not all 
GPs use electronic health record programs. The use of elec-
tronic health records in Switzerland increased from around 
40 to > 70% from 2012 to 2020 [17, 34], but remains lower 
than in other high-income countries. Furthermore, not all 
GPs who fulfil the eligibility criteria self-select to participate 
in the FIRE project. This raises the question of the repre-
sentativeness of the GPs in the FIRE database. However, 
two recent assessments of the Swiss GP workforce showed 
that the GPs in the FIRE project are comparable to the 
entire GP workforce in terms of age, sex, experience as GP 
and work percentage (eTable 2 in the supplement). These 
similarities between OPTICA, FIRE and all GPs in Switzer-
land signify that the recruitment of an externally compara-
ble sample of GPs is possible in randomized clinical trials 
in the Swiss primary care setting. This confirms previous 
evidence from the UK, which showed that achieving good 
levels of external validity was possible in clinical trials in 
primary care [52]. However, due to the lack of patient regis-
tries, we cannot comment on the comparability of patients 
in the FIRE project and Swiss patients in general. While 
the analyses presented in this manuscript do not confirm 
external validity of the forthcoming OPTICA trial results, 
they do facilitate future interpretation of our findings.
Next, inherent to routine medical databases, like the 
FIRE database, is a certain risk of information bias and 
missing data as information is only collected when it is 
clinically relevant [53]. Since we used data from before 
the OPTICA study intervention started, we assume that 
both our groups would have been affected by the same 
potential sources of bias. Despite the similarities found 
between the FIRE and Swiss GP workforce in terms of 
sociodemographic and work-related characteristics, we 
were unable to compare other important characteristics 
between the two groups (e.g. quality of care, relation-
ship and trust between doctor and patient). Our finding 
that the patients included in the OPTICA trial had less 
medication but more chronic conditions than the ref-
erence cohort could reflect the selection of “good per-
formers” which may bias the findings of the OPTICA 
trial. Our analysis of patients’ willingness to depre-
scribe was limited to patients in the OPTICA trial and 
could not be compared directly to the reference cohort 
and this questionnaire is not used in regular clinical 
care. Other limitations related to the rPATD are that it 
asks hypothetical questions, it is not specific to certain 
medications, and it might be subject to social desirabil-
ity bias. Furthermore, for the purpose of the OPTICA 
trial the rPATD was translated from English to Ger-
man; back-translation and piloting was conducted to 
increase the validity of the translation, but other meas-
ures of validation and reliability of the translation in 
the local context were not conducted (e.g. test–retest 
reliability). Finally, due to the uncertainties surround-
ing the absolute standardized differences, we decided 
to present both p-values and ASD. While there may 
be debate of the cut off to use for ASD, we used > 0.2 
as this has been recommended by Yang et Dalton [42, 
43]. If we considered a smaller threshold, such as > 0.1, 
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it would not have changed our conclusions about the 
groups being comparable.
Conclusion
In the OPTICA trial, it was possible to recruit GPs and 
their older patients with multimorbidity and polyp-
harmacy that are generally comparable to a real-world 
reference cohort of GPs and older patients with mul-
timorbidity and polypharmacy in Switzerland. The 
observed similarities between OPTICA, FIRE and all 
Swiss GPs signify that the recruitment of an externally 
valid sample of GPs is possible in randomized clinical 
trials in the Swiss primary care setting. The findings 
from this manuscript about the baseline characteristics 
of study participants will be crucial for interpreting the 
wider applicability of the OPTICA study intervention 
and its findings. Ensuring that clinical trials recruit 
comparable populations is crucial for improving the 
care of older multimorbid patients, which have previ-
ously been underrepresented in clinical research.
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